Search
Returning search results with filters:
Remove filter for
Category: Drugs
Remove filter for
Issue: Health products
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 16 - 30 of 59 items.
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
AlertHealth professional risk communication | 2022-01-17
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12
Authorization of Casirivimab and Imdevimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
AlertHealth professional risk communication | 2021-07-30
CHAMPIX (varenicline) — Potential Risk Posed by Long-Term Exposure to Nitrosamine Impurity, N-nitrosovarenicline, Exceeding Acceptable Intake Limit
AlertHealth professional risk communication | 2021-06-30
GILENYA (fingolimod) - Risk of Liver Injury
AlertHealth professional risk communication | 2021-01-18
Important Safety Information on SUBOXONE (buprenorphine and naloxone) and the Risk of Overdose or Underdose when Switching Between Dosage Forms or Routes of Administration
AlertHealth professional risk communication | 2021-01-07
Importation of German-labelled Hydromorphon Ethypharm Kalceks (Hydromorphone Hydrochloride Solution for Injection) due to Potential Shortage of Canadian-labelled HYDROmorphone
AlertHealth professional risk communication | 2021-01-06
Bacitracin for Injection (50,000 IU per vial) and the Risk of Nephrotoxicity and Anaphylactic Reactions
AlertHealth professional risk communication | 2020-12-21
ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy
AlertHealth professional risk communication | 2020-12-15
Importation of US-labelled Dexrazoxane for Injection distributed by Mylan Pharmaceuticals ULC due to shortage of Canadian-labelled Dexrazoxane
AlertHealth professional risk communication | 2020-12-01
PICATO (ingenol mebutate gel, 0.015% and 0.05%) - Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer
AlertHealth professional risk communication | 2020-10-27
Benzocaine-Containing Products and the Risk of Methemoglobinemia in Children under Two Years of Age
AlertHealth professional risk communication | 2020-10-22
FIBRISTAL (ulipristal acetate tablets, 5 mg) - Voluntary Withdrawal in Canada due to Risk of Drug-Induced Liver Injury
AlertHealth professional risk communication | 2020-09-30
Importation of US Clinical Trial-Labelled Remdesivir for Injection Due to Shortage of Canadian-Labelled Remdesivir
AlertHealth professional risk communication | 2020-09-15
ESBRIET (pirfenidone) and the Risk of Drug-Induced Liver Injury
AlertHealth professional risk communication | 2020-09-14